Showing 5571-5580 of 8847 results for "".
- Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in EBhttps://practicaldermatology.com/news/abeona-therapeutics-receives-fda-breakthrough-therapy-designation-for-eb-101-autologous-cell-therapy-in-eb/2458075/The U.S. Food and Drug Administration granted Breakthrough Therapy Designation status to the Abeona Therapeutics Inc.’s EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa. EB-101 is an autologous,&
- Study: Most Melanomas Don't Arise From Existing Moleshttps://practicaldermatology.com/news/study-most-melanomas-dont-arise-from-existing-moles/2458072/Less than one-third of melanomas (29 percent) arose from an existing mole, while the vast majority (71 percent) appeared on the skin as new spots, according to research in the Journal of the American Academy of Dermatology</
- DermTech Appoints New Member to Board of Directorshttps://practicaldermatology.com/news/dermtech-appoints-new-members-to-board-of-directors/2458080/DermTech, Inc., appointed Herman “Herm” Rosenman to its Board of Directors. Mr. Rosenman, CPA, brings more than 30 years of public company operating and financial experience to DermTech. He received a B.B.A. in finance and accounting from Pace University and an M.B.A. in finance from
- Colorescience Takes Aim at Rosacea with All Calm™ Clinical Redness Correctorhttps://practicaldermatology.com/news/colorescience-takes-aim-at-rosacea-with-all-calm-clinical-redness-corrector/2458082/Colorescience® is introducing All Calm™ Clinical Redness Corrector. Available Colorescience.com, all Calm Clinical Redness Corrector helps neutralize redness with its subtle green undertones. The patent-pending BioSolaceTM complex
- Revision Skincare Launches Nectifirm Advancedhttps://practicaldermatology.com/news/revision-skincare-launches-nectifirm-advanced/2458090/Revision Skincare® is expanding the Nectifirm® collection with Nectifirm® ADVANCED. Nectifirm® ADVANCED harnesses the power of the Microbiome for maintaining skin
- New Criteria Aims to Help Doctors Spot Amelanotic Melanoma Earlierhttps://practicaldermatology.com/news/new-criteria-aims-to-help-doctors-spot-amelanotic-melanoma-earlier/2458092/New research outlines key features linked to amelanotic melanoma. The findings, which appear in JAMA Dermatology, may help improve detection of this type of melanoma, which is more likely to be diagnosed at advanced stages because it falls outside of the “ABCDE” guide
- Dr. Larry Brilliant to Give Keynote at ASDS 2017 Meetinghttps://practicaldermatology.com/news/dr-larry-briiliant-to-give-keynote-at-asds-2017-meeting/2458097/Larry Brilliant, MD, MPH, Chair of the Skoll Global Threats Fund in San Francisco and former Vice President and Executive Director of Google, is slated to give the opening keynote address at The
- FDA Advisory Arm Backs XELJANZ for PsAhttps://practicaldermatology.com/news/fda-advisory-arm-backs-xeljanz-for-psa/2458098/The United States Food and Drug Administration’s (FDA) Arthritis Advisory Committee recommends the approval of Pfizer's XELJANZ® (tofacitinib) for the treatment of adults with active psoriatic arthritis (PsA). The Arthritis Advisory Commit
- Aclaris Submits Marketing Authorization Application in Europe for A-101 40% for Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-submits-marketing-authorization-application-in-europe-for-a-101-40-for-seborrheic-keratosis/2458100/Aclaris Therapeutics, Inc. has submitted a Marketing Authorization Application (MAA) with the Medicines Product Agency (MPA) in Sweden for its product candidate A-101 40% Topical Solution for the treatment of seborrheic keratosis. The MPA will act as the reference member state in this decentraliz
- Modernizing Medicine To Add More Than 800 Jobs in Expansionhttps://practicaldermatology.com/news/modernizing-medicine-to-add-more-than-800-jobs-in-expansion/2458101/Modernizing Medicine will expand operations and add a total of 838 jobs by 2022. The expansion, to be implemented in the historic Boca Raton Innovation Center (BRIC) in Palm Beach County will result in a capital investment of more than $15 million in the Boca Raton community.